Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials
Introduction: Chinese patent medicine (CPM) is an indispensable part of traditional Chinese medicine. Coronavirus Disease 2019 (COVID-19) manifests is an acute respiratory infectious disease. This systematic review aimed to evaluate the therapeutic effects and safety of oral CPM for COVID-19. Method...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-08-01
|
| Series: | Complementary Therapies in Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0965229921000856 |
| _version_ | 1818658229550317568 |
|---|---|
| author | Shi-Bing Liang Min Fang Chang-Hao Liang Hui-Di Lan Chen Shen Li-Jiao Yan Xiao-Yang Hu Mei Han Nicola Robinson Jian-Ping Liu |
| author_facet | Shi-Bing Liang Min Fang Chang-Hao Liang Hui-Di Lan Chen Shen Li-Jiao Yan Xiao-Yang Hu Mei Han Nicola Robinson Jian-Ping Liu |
| author_sort | Shi-Bing Liang |
| collection | DOAJ |
| description | Introduction: Chinese patent medicine (CPM) is an indispensable part of traditional Chinese medicine. Coronavirus Disease 2019 (COVID-19) manifests is an acute respiratory infectious disease. This systematic review aimed to evaluate the therapeutic effects and safety of oral CPM for COVID-19. Methods: We included randomized controlled trials (RCTs) that tested oral CPM for the treatment of COVID-19 identified from publications in CNKI, Wanfang, VIP, Web of Science, SinoMed, PubMed, Embase, BioRxiv, MedRxiv and arXiv before November 2nd, 2020. The risk of bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed using the online GRADEpro tool. Results: Seven RCTs including 1079 participants were identified. The overall bias was assessed as “-high risk of bias” for all included trials. Oral CPM investigated were: Lianhua Qingwen capsule/granules (LHQW), Jinhua Qinggan granules (JHQG), Huoxiang Zhengqi dripping pills (HXZQ), Toujie Quwen granules (TJQW) and Lianhua Qingke granules (LHQK). Compared with conventional western therapy alone for people with COVID-19: regarding the main outcomes, the results showed that oral CPM combined with conventional western therapy improved cure rate (RR = 1.20, 95 % CI 1.04–1.38, involving LHQW and TJQW), reduced aggravation rate (RR = 0.50, 95 % CI 0.29 – 0.85, involving LHQW, JHQG, LHQK and TJQW); with regard to additional outcomes, the results showed that add-on oral CPM shortened the duration of fever, cough and fatigue, improved the recovery rate of cough and fatigue, and increased the improvement and recovery rate of chest CT manifestations. There were some differences in therapeutic effects among various CPMs for the same COVID-19 outcome. The use of TJQW and LHQG appeared not to increase the risk of adverse events, but JHQG may cause mild diarrhea. Conclusion: Low-certainty or very low-certainty evidence demonstrated that oral CPM may have add-on potential therapeutic effects for patients with non-serious COVID-19. These findings need to be further confirmed by well-designed clinical trials with adequate sample sizes. |
| first_indexed | 2024-12-17T03:54:03Z |
| format | Article |
| id | doaj.art-42fd8050793140a8b32a48c501790f17 |
| institution | Directory Open Access Journal |
| issn | 0965-2299 |
| language | English |
| last_indexed | 2024-12-17T03:54:03Z |
| publishDate | 2021-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Complementary Therapies in Medicine |
| spelling | doaj.art-42fd8050793140a8b32a48c501790f172022-12-21T22:04:40ZengElsevierComplementary Therapies in Medicine0965-22992021-08-0160102744Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trialsShi-Bing Liang0Min Fang1Chang-Hao Liang2Hui-Di Lan3Chen Shen4Li-Jiao Yan5Xiao-Yang Hu6Mei Han7Nicola Robinson8Jian-Ping Liu9Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Guangxi University of Chinese Medicine, Guangxi, 530000, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaPrimary Care and Population Sciences, Faculty of Medicine, University of Southampton, SO16 5ST, United Kingdom; Research Design Service South Central, National Institute of Health Research, SO16 6YD, United KingdomCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Institute of Health and Social Care, London South Bank University, London, SE1 0AA, United KingdomCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Institute of Integrated Traditional Chinese Medicine and Western Medicine, Guangzhou Medical University, Guangzhou, 510120, China; Corresponding author at: Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.Introduction: Chinese patent medicine (CPM) is an indispensable part of traditional Chinese medicine. Coronavirus Disease 2019 (COVID-19) manifests is an acute respiratory infectious disease. This systematic review aimed to evaluate the therapeutic effects and safety of oral CPM for COVID-19. Methods: We included randomized controlled trials (RCTs) that tested oral CPM for the treatment of COVID-19 identified from publications in CNKI, Wanfang, VIP, Web of Science, SinoMed, PubMed, Embase, BioRxiv, MedRxiv and arXiv before November 2nd, 2020. The risk of bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed using the online GRADEpro tool. Results: Seven RCTs including 1079 participants were identified. The overall bias was assessed as “-high risk of bias” for all included trials. Oral CPM investigated were: Lianhua Qingwen capsule/granules (LHQW), Jinhua Qinggan granules (JHQG), Huoxiang Zhengqi dripping pills (HXZQ), Toujie Quwen granules (TJQW) and Lianhua Qingke granules (LHQK). Compared with conventional western therapy alone for people with COVID-19: regarding the main outcomes, the results showed that oral CPM combined with conventional western therapy improved cure rate (RR = 1.20, 95 % CI 1.04–1.38, involving LHQW and TJQW), reduced aggravation rate (RR = 0.50, 95 % CI 0.29 – 0.85, involving LHQW, JHQG, LHQK and TJQW); with regard to additional outcomes, the results showed that add-on oral CPM shortened the duration of fever, cough and fatigue, improved the recovery rate of cough and fatigue, and increased the improvement and recovery rate of chest CT manifestations. There were some differences in therapeutic effects among various CPMs for the same COVID-19 outcome. The use of TJQW and LHQG appeared not to increase the risk of adverse events, but JHQG may cause mild diarrhea. Conclusion: Low-certainty or very low-certainty evidence demonstrated that oral CPM may have add-on potential therapeutic effects for patients with non-serious COVID-19. These findings need to be further confirmed by well-designed clinical trials with adequate sample sizes.http://www.sciencedirect.com/science/article/pii/S0965229921000856Coronavirus Disease 2019COVID-19Chinese patent medicineChinese herbal medicineSystematic reviewMeta-analysis |
| spellingShingle | Shi-Bing Liang Min Fang Chang-Hao Liang Hui-Di Lan Chen Shen Li-Jiao Yan Xiao-Yang Hu Mei Han Nicola Robinson Jian-Ping Liu Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials Complementary Therapies in Medicine Coronavirus Disease 2019 COVID-19 Chinese patent medicine Chinese herbal medicine Systematic review Meta-analysis |
| title | Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials |
| title_full | Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials |
| title_short | Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials |
| title_sort | therapeutic effects and safety of oral chinese patent medicine for covid 19 a rapid systematic review and meta analysis of randomized controlled trials |
| topic | Coronavirus Disease 2019 COVID-19 Chinese patent medicine Chinese herbal medicine Systematic review Meta-analysis |
| url | http://www.sciencedirect.com/science/article/pii/S0965229921000856 |
| work_keys_str_mv | AT shibingliang therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT minfang therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT changhaoliang therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT huidilan therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chenshen therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT lijiaoyan therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT xiaoyanghu therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT meihan therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT nicolarobinson therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jianpingliu therapeuticeffectsandsafetyoforalchinesepatentmedicineforcovid19arapidsystematicreviewandmetaanalysisofrandomizedcontrolledtrials |